Plegridy

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

peginterferon beta-1a

Disponible depuis:

Biogen Netherlands B.V.

Code ATC:

L03AB13

DCI (Dénomination commune internationale):

peginterferon beta-1a

Groupe thérapeutique:

Immunostimulants,

Domaine thérapeutique:

Multiple Sclerosis

indications thérapeutiques:

Treatment of relapsing remitting multiple sclerosis in adult patients.

Descriptif du produit:

Revision: 24

Statut de autorisation:

Authorised

Date de l'autorisation:

2014-07-18

Notice patient

                                50
B. PACKAGE LEAFLET
51
PACKAGE LEAFLET: INFORMATION FOR THE USER
PLEGRIDY 63 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
PLEGRIDY 94 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
PLEGRIDY 125 MICROGRAMS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
peginterferon beta-1a
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
WHAT PLEGRIDY IS AND WHAT IT IS USED FOR
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE PLEGRIDY
3.
HOW TO USE PLEGRIDY
4.
POSSIBLE SIDE EFFECTS
5.
HOW TO STORE PLEGRIDY
6.
CONTENTS OF THE PACK AND OTHER INFORMATION
7.
INSTRUCTIONS FOR INJECTING PLEGRIDY PRE-FILLED SYRINGE
1.
WHAT PLEGRIDY IS AND WHAT IT IS USED FOR
WHAT PLEGRIDY IS
The active substance in Plegridy is peginterferon beta-1a.
Peginterferon beta-1a is a modified
long-acting form of interferon. Interferons are natural substances
made in the body to help protect
from infections and diseases.
WHAT PLEGRIDY IS USED FOR
THIS MEDICINE IS USED TO TREAT RELAPSING-REMITTING MULTIPLE SCLEROSIS
(MS) IN ADULTS AGED 18 OR
OVER.
MS is a long term illness that affects the central nervous system
(CNS), including the brain and spinal
cord, in which the body’s immune system (its natural defences)
damages the protective layer (myelin)
that surrounds the nerves in the brain and spinal cord. This disrupts
the messages between the brain
and other parts of the body, causing the symptoms of MS. Patients with
relapsing-remitting MS have
periods when the disease is not active (remission) in between
flare-ups of symptom
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Plegridy 63 micrograms solution for injection in pre-filled syringe
Plegridy 94 micrograms solution for injection in pre-filled syringe
Plegridy 125 micrograms solution for injection in pre-filled syringe
Plegridy 63 micrograms solution for injection in pre-filled pen
Plegridy 94 micrograms solution for injection in pre-filled pen
Plegridy 125 micrograms solution for injection in pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Plegridy 63 micrograms solution for injection in pre-filled syringe
(for subcutaneous use)
Each pre-filled syringe contains 63 micrograms of peginterferon
beta-1a* in 0.5 mL solution for
injection.
Plegridy 94 micrograms solution for injection in pre-filled syringe
(for subcutaneous use)
Each pre-filled syringe contains 94
micrograms of peginterferon beta-1a* in 0.5 mL solution for
injection.
Plegridy 125 micrograms solution for injection in pre-filled syringe
(for subcutaneous use)
Each pre-filled syringe contains 125 micrograms of peginterferon
beta-1a* in 0.5 mL solution for
injection.
Plegridy 125 micrograms solution for injection in pre-filled syringe
(for intramuscular use)
Each pre-filled syringe contains 125 micrograms of peginterferon
beta-1a* in 0.5 mL solution for
injection.
Plegridy 63 micrograms solution for injection in pre-filled pen (for
subcutaneous use)
Each pre-filled pen contains 63 micrograms of peginterferon beta-1a*
in 0.5 mL solution for injection.
Plegridy 94 micrograms solution for injection in pre-filled pen (for
subcutaneous use)
Each pre-filled pen contains 94 micrograms of peginterferon beta-1a*
in 0.5 mL solution for injection.
Plegridy 125 micrograms solution for injection in pre-filled pen (for
subcutaneous use)Each pre-filled
pen contains 125 micrograms of peginterferon beta-1a* in 0.5 mL
solution for injection.
The dose indicates the quantity of the interferon beta-1a moiety of
peginterferon beta-1a without
consideration of the PEG moiety attached.
*The active sub
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation bulgare 22-12-2020
Notice patient Notice patient espagnol 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation espagnol 22-12-2020
Notice patient Notice patient tchèque 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation tchèque 22-12-2020
Notice patient Notice patient danois 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation danois 22-12-2020
Notice patient Notice patient allemand 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation allemand 22-12-2020
Notice patient Notice patient estonien 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation estonien 22-12-2020
Notice patient Notice patient grec 25-04-2023
Notice patient Notice patient français 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation français 22-12-2020
Notice patient Notice patient italien 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation italien 22-12-2020
Notice patient Notice patient letton 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation letton 22-12-2020
Notice patient Notice patient lituanien 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation lituanien 22-12-2020
Notice patient Notice patient hongrois 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation hongrois 22-12-2020
Notice patient Notice patient maltais 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation maltais 22-12-2020
Notice patient Notice patient néerlandais 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation néerlandais 22-12-2020
Notice patient Notice patient polonais 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation polonais 22-12-2020
Notice patient Notice patient portugais 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation portugais 22-12-2020
Notice patient Notice patient roumain 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation roumain 22-12-2020
Notice patient Notice patient slovaque 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation slovaque 22-12-2020
Notice patient Notice patient slovène 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation slovène 22-12-2020
Notice patient Notice patient finnois 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation finnois 22-12-2020
Notice patient Notice patient suédois 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation suédois 22-12-2020
Notice patient Notice patient norvégien 25-04-2023
Notice patient Notice patient islandais 25-04-2023
Notice patient Notice patient croate 25-04-2023
Rapport public d'évaluation Rapport public d'évaluation croate 22-12-2020

Rechercher des alertes liées à ce produit

Afficher l'historique des documents